ENXTBR:ARGXBiotechs
Does Wells Fargo’s Q3 Tactical Pick Call Reframe argenx’s (ENXTBR:ARGX) Autoimmune Pipeline Narrative?
In late June 2026, Wells Fargo named argenx a top Q3 tactical pick, highlighting an upcoming clinical catalyst as a key focus for investors.
This endorsement brings fresh attention to how argenx’s pipeline progress and near-term milestones could influence expectations for its autoimmune portfolio.
We’ll now examine how Wells Fargo’s Q3 tactical pick call and the looming clinical catalyst feed into argenx’s existing investment narrative.
The future of work is here. Discover the 29 top...